HealthEquity, Inc. (NASDAQ:HQY – Get Free Report) Director Robert W. Selander sold 5,750 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total value of $639,917.50. Following the sale, the director now directly owns 78,219 shares in the company, valued at $8,704,992.51. The trade was a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
HealthEquity Stock Down 1.1 %
Shares of NASDAQ:HQY opened at $112.69 on Friday. HealthEquity, Inc. has a 52-week low of $65.01 and a 52-week high of $115.59. The stock has a market cap of $9.77 billion, a P/E ratio of 103.39, a price-to-earnings-growth ratio of 1.61 and a beta of 0.55. The business’s 50 day moving average is $102.14 and its 200 day moving average is $90.76. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51.
HealthEquity (NASDAQ:HQY – Get Free Report) last posted its earnings results on Monday, December 9th. The company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same period in the previous year, the business posted $0.40 EPS. Sell-side analysts predict that HealthEquity, Inc. will post 2.32 EPS for the current year.
Institutional Trading of HealthEquity
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on HQY shares. Bank of America boosted their price objective on HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Barrington Research upped their target price on HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. JMP Securities upped their target price on HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 10th. BTIG Research upped their target price on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Finally, Mizuho initiated coverage on HealthEquity in a research note on Wednesday, December 4th. They set an “outperform” rating and a $126.00 target price on the stock. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $110.71.
Get Our Latest Research Report on HealthEquity
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories
- Five stocks we like better than HealthEquity
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- How to Invest in the Best Canadian Stocks
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- High Flyers: 3 Natural Gas Stocks for March 2022
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.